Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.
Saved in:
| Title: | Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy. |
|---|---|
| Authors: | Bastos, Paulo (AUTHOR), Kermorgant, Marc (AUTHOR), Ory‐Magne, Fabienne (AUTHOR), Leung, Clémence (AUTHOR), Fabbri, Margherita (AUTHOR), Rascol, Olivier (AUTHOR), Foubert‐Samier, Alexandra (AUTHOR), Bendetowicz, David (AUTHOR), Meissner, Wassilios G. (AUTHOR), Pavy‐le‐Traon, Anne (AUTHOR) |
| Source: | European Journal of Neurology. Jun2026, Vol. 33 Issue 6, p1-11. 11p. |
| Subjects: | Multiple system atrophy, Biomarkers, Dysautonomia, Disease progression, Death forecasting, Sweat glands, Longitudinal method |
| Abstract: | Background: Multiple system atrophy (MSA) is characterized by progressive autonomic/motor dysfunction, but robust biomarkers do not exist. Electrochemical skin conductance (ESC) provides a noninvasive measure of sudomotor function, but its longitudinal predictive value and prognostic relevance in MSA remain insufficiently studied. We aimed to comprehensively evaluate ESC in a large longitudinal cohort. Methods: We analyzed 175 patients with MSA followed for a mean of 4.2 ± 2.1 years. Disease severity was assessed using UMSARS Parts 1 and 2, COMPASS31, SCOPA‐AUT, and orthostatic blood pressure (BP) measurements. Hand and foot ESC were measured using Sudoscan. Cross‐sectional and longitudinal associations were examined using linear mixed‐effects models, repeated‐measures correlations, and grouped 10‐fold cross‐validation. Mortality predictors were assessed with time‐varying Cox proportional hazards models. Results: ESC was strongly inversely associated with UMSARS 1 and 2 (β = −0.58 to −0.65; r = −0.67 to −0.75; all p < 0.0001), whereas associations with orthostatic BP, autonomic symptom scales, and disease duration were weaker or inconsistent. ESC declined significantly over time (feet −6.88 ± 0.60 μS/year; hands −5.41 ± 0.46 μS/year; both p < 0.001), paralleling UMSARS progression. ESC outperformed orthostatic BP drops in predicting UMSARS scores in mixed‐effects models and cross‐validation. Higher ESC independently predicted lower mortality, while higher UMSARS scores and greater orthostatic BP drops predicted increased risk. Median survival was 46.2 months. Conclusions: ESC is a sensitive biomarker of disease severity, progression, and survival in MSA, substantially outperforming orthostatic BP measures. Its simplicity and prognostic value support incorporation into routine monitoring and clinical trials. [ABSTRACT FROM AUTHOR] |
| Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Multiple system atrophy (MSA) is characterized by progressive autonomic/motor dysfunction, but robust biomarkers do not exist. Electrochemical skin conductance (ESC) provides a noninvasive measure of sudomotor function, but its longitudinal predictive value and prognostic relevance in MSA remain insufficiently studied. We aimed to comprehensively evaluate ESC in a large longitudinal cohort. Methods: We analyzed 175 patients with MSA followed for a mean of 4.2 ± 2.1 years. Disease severity was assessed using UMSARS Parts 1 and 2, COMPASS31, SCOPA‐AUT, and orthostatic blood pressure (BP) measurements. Hand and foot ESC were measured using Sudoscan. Cross‐sectional and longitudinal associations were examined using linear mixed‐effects models, repeated‐measures correlations, and grouped 10‐fold cross‐validation. Mortality predictors were assessed with time‐varying Cox proportional hazards models. Results: ESC was strongly inversely associated with UMSARS 1 and 2 (β = −0.58 to −0.65; r = −0.67 to −0.75; all p < 0.0001), whereas associations with orthostatic BP, autonomic symptom scales, and disease duration were weaker or inconsistent. ESC declined significantly over time (feet −6.88 ± 0.60 μS/year; hands −5.41 ± 0.46 μS/year; both p < 0.001), paralleling UMSARS progression. ESC outperformed orthostatic BP drops in predicting UMSARS scores in mixed‐effects models and cross‐validation. Higher ESC independently predicted lower mortality, while higher UMSARS scores and greater orthostatic BP drops predicted increased risk. Median survival was 46.2 months. Conclusions: ESC is a sensitive biomarker of disease severity, progression, and survival in MSA, substantially outperforming orthostatic BP measures. Its simplicity and prognostic value support incorporation into routine monitoring and clinical trials. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13515101 |
| DOI: | 10.1111/ene.70620 |
